Professor Ignace Vergote conducts 20 ovarian cancer trials per year and has authored more than 800 papers in gynecologic cancers. He was an investigator in Novocure’s phase 2 pilot trial in recurrent ovarian cancer, INNOVATE.
Tobias Weizel, Novocure’s General Manager Germany, leads the company’s commercial business in Germany and said he feels lucky to be a part of Novocure’s mission of bringing a profoundly different cancer treatment to patients worldwide.
Our second generation Optune System is smaller and less than half the weight of our first generation Optune System. See more on the innovation behind our redesigned Tumor Treating Fields delivery system.
Our Device Support Specialists (DSSs) work one-on-one with patients — educating them about the device, and providing technical support and personal contact with Novocure. Learn more about Amy Luton, one of our DSSs in Texas.